Intrinsic value of Adamis Pharmaceuticals Corporation - ADMP

Previous Close

$1.39

  Intrinsic Value

$0.17

stock screener

  Rating & Target

str. sell

-88%

Previous close

$1.39

 
Intrinsic value

$0.17

 
Up/down potential

-88%

 
Rating

str. sell

We calculate the intrinsic value of ADMP stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  13.10
  12.29
  11.56
  10.90
  10.31
  9.78
  9.30
  8.87
  8.49
  8.14
  7.82
  7.54
  7.29
  7.06
  6.85
  6.67
  6.50
  6.35
  6.22
  6.09
  5.98
  5.89
  5.80
  5.72
  5.65
  5.58
  5.52
  5.47
  5.42
  5.38
Revenue, $m
  15
  17
  18
  20
  23
  25
  27
  29
  32
  35
  37
  40
  43
  46
  49
  52
  56
  59
  63
  67
  71
  75
  79
  84
  89
  94
  99
  104
  110
  116
Variable operating expenses, $m
  15
  16
  18
  20
  22
  24
  26
  29
  31
  33
  35
  38
  41
  44
  47
  50
  53
  56
  60
  63
  67
  71
  75
  79
  84
  89
  94
  99
  104
  110
Fixed operating expenses, $m
  28
  28
  29
  29
  30
  31
  31
  32
  33
  34
  34
  35
  36
  37
  37
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
Total operating expenses, $m
  43
  44
  47
  49
  52
  55
  57
  61
  64
  67
  69
  73
  77
  81
  84
  88
  92
  96
  101
  105
  110
  115
  120
  125
  131
  137
  143
  149
  155
  162
Operating income, $m
  -28
  -28
  -29
  -29
  -30
  -30
  -31
  -31
  -32
  -32
  -32
  -33
  -34
  -34
  -35
  -35
  -36
  -37
  -37
  -38
  -39
  -40
  -40
  -41
  -42
  -42
  -43
  -44
  -45
  -46
EBITDA, $m
  -25
  -25
  -25
  -25
  -26
  -26
  -26
  -26
  -27
  -27
  -27
  -27
  -28
  -28
  -28
  -28
  -28
  -28
  -29
  -29
  -29
  -29
  -29
  -29
  -29
  -29
  -29
  -29
  -29
  -29
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
Earnings before tax, $m
  -28
  -28
  -29
  -30
  -30
  -31
  -31
  -32
  -33
  -33
  -33
  -34
  -35
  -36
  -36
  -37
  -38
  -39
  -40
  -40
  -41
  -42
  -43
  -44
  -45
  -46
  -47
  -48
  -49
  -50
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -28
  -28
  -29
  -30
  -30
  -31
  -31
  -32
  -33
  -33
  -33
  -34
  -35
  -36
  -36
  -37
  -38
  -39
  -40
  -40
  -41
  -42
  -43
  -44
  -45
  -46
  -47
  -48
  -49
  -50

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  45
  50
  56
  62
  68
  75
  82
  89
  97
  105
  113
  121
  130
  139
  149
  159
  169
  180
  191
  203
  215
  228
  241
  255
  269
  284
  300
  316
  333
  351
Adjusted assets (=assets-cash), $m
  45
  50
  56
  62
  68
  75
  82
  89
  97
  105
  113
  121
  130
  139
  149
  159
  169
  180
  191
  203
  215
  228
  241
  255
  269
  284
  300
  316
  333
  351
Revenue / Adjusted assets
  0.333
  0.340
  0.321
  0.323
  0.338
  0.333
  0.329
  0.326
  0.330
  0.333
  0.327
  0.331
  0.331
  0.331
  0.329
  0.327
  0.331
  0.328
  0.330
  0.330
  0.330
  0.329
  0.328
  0.329
  0.331
  0.331
  0.330
  0.329
  0.330
  0.330
Average production assets, $m
  20
  23
  26
  28
  31
  34
  37
  41
  44
  48
  52
  55
  60
  64
  68
  73
  77
  82
  87
  93
  98
  104
  110
  116
  123
  130
  137
  144
  152
  160
Working capital, $m
  -4
  -4
  -4
  -5
  -5
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -22
  -23
  -24
  -25
  -27
  -28
Total debt, $m
  6
  8
  9
  10
  12
  14
  15
  17
  19
  21
  23
  25
  27
  29
  31
  34
  36
  39
  41
  44
  47
  50
  53
  56
  60
  63
  67
  71
  75
  79
Total liabilities, $m
  11
  12
  13
  15
  16
  18
  20
  21
  23
  25
  27
  29
  31
  33
  35
  38
  40
  43
  45
  48
  51
  54
  57
  61
  64
  68
  71
  75
  79
  84
Total equity, $m
  34
  38
  43
  47
  52
  57
  62
  68
  74
  80
  86
  92
  99
  106
  113
  121
  129
  137
  146
  155
  164
  173
  183
  194
  205
  216
  228
  241
  254
  268
Total liabilities and equity, $m
  45
  50
  56
  62
  68
  75
  82
  89
  97
  105
  113
  121
  130
  139
  148
  159
  169
  180
  191
  203
  215
  227
  240
  255
  269
  284
  299
  316
  333
  352
Debt-to-equity ratio
  0.190
  0.200
  0.210
  0.220
  0.230
  0.240
  0.240
  0.250
  0.250
  0.260
  0.260
  0.270
  0.270
  0.270
  0.270
  0.280
  0.280
  0.280
  0.280
  0.280
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.300
  0.300
Adjusted equity ratio
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -28
  -28
  -29
  -30
  -30
  -31
  -31
  -32
  -33
  -33
  -33
  -34
  -35
  -36
  -36
  -37
  -38
  -39
  -40
  -40
  -41
  -42
  -43
  -44
  -45
  -46
  -47
  -48
  -49
  -50
Depreciation, amort., depletion, $m
  3
  3
  3
  4
  4
  4
  4
  5
  5
  6
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  10
  11
  11
  12
  12
  13
  14
  15
  15
  16
Funds from operations, $m
  -25
  -25
  -26
  -26
  -26
  -27
  -27
  -27
  -28
  -28
  -28
  -29
  -29
  -29
  -29
  -30
  -30
  -30
  -31
  -31
  -31
  -32
  -32
  -32
  -32
  -33
  -33
  -33
  -33
  -33
Change in working capital, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -25
  -25
  -25
  -25
  -26
  -26
  -26
  -27
  -27
  -27
  -28
  -28
  -28
  -28
  -29
  -29
  -29
  -30
  -30
  -30
  -30
  -31
  -31
  -31
  -31
  -31
  -32
  -32
  -32
  -32
Maintenance CAPEX, $m
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -11
  -11
  -12
  -12
  -13
  -14
  -15
  -15
New CAPEX, $m
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
  -8
Cash from investing activities, $m
  -4
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -8
  -9
  -9
  -10
  -10
  -10
  -12
  -12
  -13
  -13
  -14
  -15
  -16
  -17
  -17
  -19
  -19
  -20
  -21
  -23
  -23
Free cash flow, $m
  -29
  -29
  -30
  -31
  -32
  -32
  -33
  -34
  -35
  -35
  -36
  -37
  -38
  -39
  -39
  -40
  -41
  -42
  -43
  -44
  -45
  -46
  -47
  -48
  -50
  -51
  -52
  -53
  -54
  -56
Issuance/(repayment) of debt, $m
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
Issuance/(repurchase) of shares, $m
  32
  33
  33
  34
  35
  36
  37
  38
  39
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  52
  53
  54
  56
  57
  59
  60
  62
  63
Cash from financing (excl. dividends), $m  
  33
  34
  34
  35
  37
  38
  39
  40
  41
  41
  42
  43
  44
  45
  46
  47
  48
  50
  51
  52
  53
  55
  56
  57
  59
  61
  63
  64
  66
  67
Total cash flow (excl. dividends), $m
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  5
  6
  6
  6
  6
  7
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
  11
  12
Retained Cash Flow (-), $m
  -32
  -33
  -33
  -34
  -35
  -36
  -37
  -38
  -39
  -39
  -40
  -41
  -42
  -43
  -44
  -45
  -46
  -47
  -48
  -49
  -50
  -52
  -53
  -54
  -56
  -57
  -59
  -60
  -62
  -63
Prev. year cash balance distribution, $m
  10
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -18
  -28
  -29
  -29
  -30
  -31
  -31
  -32
  -33
  -33
  -34
  -35
  -36
  -36
  -37
  -38
  -39
  -40
  -41
  -41
  -42
  -43
  -44
  -45
  -46
  -47
  -48
  -49
  -50
  -51
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -17
  -26
  -25
  -24
  -23
  -22
  -21
  -20
  -19
  -18
  -16
  -15
  -14
  -12
  -11
  -10
  -8
  -7
  -6
  -5
  -4
  -4
  -3
  -2
  -2
  -1
  -1
  -1
  -1
  0
Current shareholders' claim on cash, %
  61.1
  38.8
  25.4
  17.1
  11.8
  8.4
  6.0
  4.4
  3.3
  2.5
  1.9
  1.5
  1.2
  0.9
  0.8
  0.6
  0.5
  0.4
  0.3
  0.3
  0.2
  0.2
  0.2
  0.1
  0.1
  0.1
  0.1
  0.1
  0.1
  0.1

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

FINANCIAL RATIOS  of  Adamis Pharmaceuticals Corporation (ADMP)

Valuation Ratios
P/E Ratio -1.6
Price to Sales 5.1
Price to Book 1.2
Price to Tangible Book
Price to Cash Flow -1.5
Price to Free Cash Flow -1.5
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 12%
Total Debt to Equity 28%
Interest Coverage 0
Management Effectiveness
Return On Assets -76%
Ret/ On Assets - 3 Yr. Avg. -84.1%
Return On Total Capital -92.7%
Ret/ On T. Cap. - 3 Yr. Avg. -107.3%
Return On Equity -111.8%
Return On Equity - 3 Yr. Avg. -113.7%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 33.3%
Gross Margin - 3 Yr. Avg. 11.1%
EBITDA Margin -350%
EBITDA Margin - 3 Yr. Avg. -116.7%
Operating Margin -433.3%
Oper. Margin - 3 Yr. Avg. -144.4%
Pre-Tax Margin -400%
Pre-Tax Margin - 3 Yr. Avg. -133.3%
Net Profit Margin -316.7%
Net Profit Margin - 3 Yr. Avg. -105.6%
Effective Tax Rate 20.8%
Eff/ Tax Rate - 3 Yr. Avg. 6.9%
Payout Ratio 0%

ADMP stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ADMP stock intrinsic value calculation we used $13 million for the last fiscal year's total revenue generated by Adamis Pharmaceuticals Corporation. The default revenue input number comes from 0001 income statement of Adamis Pharmaceuticals Corporation. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ADMP stock valuation model: a) initial revenue growth rate of 13.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ADMP is calculated based on our internal credit rating of Adamis Pharmaceuticals Corporation, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Adamis Pharmaceuticals Corporation.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ADMP stock the variable cost ratio is equal to 100%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $27 million in the base year in the intrinsic value calculation for ADMP stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Adamis Pharmaceuticals Corporation.

Corporate tax rate of 27% is the nominal tax rate for Adamis Pharmaceuticals Corporation. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ADMP stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ADMP are equal to 138.5%.

Life of production assets of 9.9 years is the average useful life of capital assets used in Adamis Pharmaceuticals Corporation operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ADMP is equal to -24.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $39.547484 million for Adamis Pharmaceuticals Corporation - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 47.292 million for Adamis Pharmaceuticals Corporation is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Adamis Pharmaceuticals Corporation at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
GSK GlaxoSmithKlin 40.12 65.66  str.buy
BDX Becton, Dickin 234.16 396.45  str.buy
MYL Mylan N.V. 17.02 47.49  str.buy
ACET Aceto Corporat 0.174 18.20  str.buy
AKRX Akorn, Inc. 4.25 1.92  sell
LCI Lannett Co Inc 5.22 24.03  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.